Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-37760
Titel: Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer : results of the PREFERE trial
VerfasserIn: Albers, Peter
Wiegel, Thomas
Schmidberger, Heinz
Bussar-Maatz, Roswitha
Härter, Martin
Kristiansen, Glen
Martus, Peter
Meisner, Christoph
Wellek, Stefan
Grozinger, Klaus
Renner, Peter
Burmester, Martin
Schneider, Fried
Stöckle, Michael
Sprache: Englisch
Titel: World Journal of Urology
Bandnummer: 39 (2021)
Heft: 1
Seiten: 65–72
Verlag/Plattform: Springer Nature
Erscheinungsjahr: 2020
Freie Schlagwörter: Active surveillance
Prostate cancer
Clinical trial
Reclassifcation
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Purpose Active surveillance (AS) strategies for patients with low- and early intermediate-risk prostate cancer are still not consistently defined. Within a controlled randomized trial, active surveillance was compared to other treatment options for patients with prostate cancer. Aim of this analysis was to report on termination rates of patients treated with AS including different grade groups. Methods A randomized trial comparing radical prostatectomy, active surveillance, external beam radiotherapy and brachytherapy was performed from 2013 to 2016 and included 345 patients with low- and early intermediate-risk prostate cancer (ISUP grade groups 1 and 2). The trial was prematurely stopped due to slow accrual. A total of 130 patients were treated with active surveillance. Among them, 42 patients were diagnosed with intermediate-risk PCA. Reference pathology and AS quality control were performed throughout. Results After a median follow-up time of 18.8 months, 73 out of the 130 patients (56%) terminated active surveillance. Of these, 56 (77%) patients were histologically reclassified at the time of rebiopsy, including 35% and 60% of the grade group 1 and 2 patients, respectively. No patients who underwent radical prostatectomy at the time of reclassification had radical prostatectomy specimens ≥ grade group 3. Conclusion In this prospectively analyzed subcohort of patients with AS and conventional staging within a randomized trial, the 2-year histological reclassification rates were higher than those previously reported. Active surveillance may not be based on conventional staging alone, and patients with grade group 2 cancers may be recommended for active surveillance in carefully controlled trials only.
DOI der Erstveröffentlichung: 10.1007/s00345-020-03154-7
URL der Erstveröffentlichung: https://link.springer.com/article/10.1007/s00345-020-03154-7
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-377605
hdl:20.500.11880/34155
http://dx.doi.org/10.22028/D291-37760
ISSN: 1433-8726
0724-4983
Datum des Eintrags: 28-Okt-2022
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Urologie und Kinderurologie
Professur: M - Prof. Dr. Michael Stöckle
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
s00345-020-03154-7.pdf729,2 kBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons